Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.

Autor: Leiter LA; Division of Endocrinology & Metabolism, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Teoh H; Division of Endocrinology & Metabolism, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.; Division of Cardiac Surgery, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada., Mosenzon O; Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University-Medical Center, Jerusalem, Israel., Cahn A; Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University-Medical Center, Jerusalem, Israel., Hirshberg B; AstraZeneca, Wilmington, DE, USA., Stahre CA; AstraZeneca, Mölndal, Sweden., Hoekstra JB; Internal Medicine, University of Amsterdam, Amsterdam, Netherlands., Alvarsson M; Molecular Medicine and Surgery, Endocrinology, Metabolism and Diabetes, Karolinska Institutet Solna, Stockholm, Sweden., Im K; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Scirica BM; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Bhatt DL; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Raz I; Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University-Medical Center, Jerusalem, Israel.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2016 Feb; Vol. 18 (2), pp. 186-90. Date of Electronic Publication: 2015 Nov 27.